Researchers are cautiously optimistic following companies’ announcement of positive results for lecanemab Some researchers are celebrating this week’s announcement that a drug candidate for Alzheimer’s disease slowed the rate of cognitive decline for people in a clinical trial by 27%. Others, however, remain hesitant, wanting to see data beyond what was disclosed in a 27…